Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
May 15th, 2025
News
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
May 14th, 2025
Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
April 21st, 2025
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 8th, 2025
Applied DNA Positions TR8 PGx Testing Service as Pre-emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
April 1st, 2025
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
March 26th, 2025
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
March 12th, 2025
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
February 13th, 2025
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
February 12th, 2025